Navigation Links
Raymond J. Ruddy Joins Psychemedics Corporation As Top Financial Officer
Date:10/20/2008

ACTON, Mass., Oct. 20 /PRNewswire-FirstCall/ -- Psychemedics Corporation (Nasdaq: PMD) today announced that Raymond J. Ruddy has joined the company as Vice President, Controller.

Ray will be responsible for all internal and external financial reporting activities, as well as the financial analysis and planning activities necessary for the company's continued growth. Ray will report directly to the Chairman and CEO.

Since 2005, Ray has served as Director of International Finance of GSI Group Corporation. From 2001 to 2005 Ray served as Director of Finance and Investor Relations of Concord Communications. He began his career in the audit department at Ernest & Young LLP and proceeded to work in positions of increasing responsibilities with three additional firms before joining Concord Communications. Ray is a CPA who received his BA from The College of the Holy Cross and his MBA from the Yale University School of Management.

Raymond C. Kubacki, Chairman and CEO stated, "We are extremely pleased to have Ray join our team. He comes to us with a strong proven track record that fits extremely well with the needs of our company. His strong analytical skills and broad experience base will be very important in determining and controlling costs and expenses, as well as analyzing other key metrics in our business needed to accelerate our growth. Ray will be our top financial officer and we are extremely pleased to have him on board."

Psychemedics is the world's largest provider of testing for drugs of abuse using hair analysis with thousands of corporations relying on the patented Psychemedics drug testing services. Psychemedics' clients include over 10% of the Fortune 500, some of the largest police departments in America and Federal Reserve Banks.

The Psychemedics web site is http://www.drugtestwithhair.com

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning growth, earnings, profit margins, earnings per share, revenues, dividends, future business, new accounts, customer base, market share, test volume and sales and marketing strategies) may be "forward-looking" statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company's sales and marketing network, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.

Contact: Raymond C. Kubacki

Chairman, President and CEO

(978) 206-8220


'/>"/>
SOURCE Psychemedics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Statement by American Heart Association Immediate-Past President Raymond Gibbons, M.D. on Congressional Omnibus Spending Bill
2. SXC Health Solutions to present at Raymond James 29th Annual Institutional Investors Conference
3. Gentiva(R) Health Services to Present March 3rd at Raymond James 29th Annual Institutional Investors Conference in Orlando
4. MedCath Corporation to Present at the Raymond James 29th Annual Institutional Investors Conference
5. Hologic to Present at the Raymond James & Associates 29th Annual Institutional Investors Conference
6. Aflac Incorporated to Present at the Raymond James 29th Annual Institutional Investors Conference
7. Covance to Present at Raymond James 29th Annual Institutional Investors Conference
8. Emageon to Present at Raymond James 29th Annual Institutional Investors Conference
9. Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors
10. Richard Greco Joins Mediware Board
11. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... ... century approach to infusing high speed technology into the fabric of an entire ... the advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere ... Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is ... of providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... joined the Peoples Health network on Dec. 1, 2016. Peoples Health, a Metairie-based ... Medical Center is an exciting addition to our provider network, and the addition ...
(Date:1/17/2017)... ... 2017 , ... A prescription medication bottle, pocket knife, luggage and a solar-powered ... Product Design Challenge , the Cradle to Cradle Products Innovation Institute has ... scheduled to run through early 2018. The challenges are presented by the Institute in ...
(Date:1/17/2017)... Livingston, NJ (PRWEB) , ... January 17, 2017 , ... ... services and financial planning assistance to communities throughout the region, is launching a charity ... , Heart disease is by far the deadliest killer in America, and is responsible ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... BALTIMORE , Jan. 17, 2017 Paragon ... to provide product development services for a variety ... Diseases (NIAID) medical product development activities. The ... a contractor pool for task order awards up ... global leader in manufacturing and process development of ...
(Date:1/17/2017)... Management to Discuss Acquisition of Oncology ... On Track For An NDA Submission to ...   ... KTOV ; TASE: KTOV), an innovative biopharmaceutical company, announced that it will ... Eastern Time to discuss the recent acquisition of a majority stake in TyrNovo, ...
(Date:1/17/2017)... Jan. 17, 2017  Jazz Pharmaceuticals plc (Nasdaq: ... been enrolled in a Phase 3 clinical trial comparing ... care (BSC) in the prevention of hepatic veno-occlusive disease ... cell transplant (HSCT) who are at high risk or ... clinical trial will be conducted across approximately 100 medical ...
Breaking Medicine Technology: